Florida Regulations 64B16-26.302: Subject Matter for Consultant Pharmacist Licensure Renewal Continuing Education
Current as of: 2024 | Check for updates
|
Other versions
A Consultant Pharmacist License Renewal Continuing Education Program must contain at least three (3) hours of training in any of the subjects specified below. Duplicate courses are not acceptable.
(1) Drug Therapy – Disease State. Patient Drug Therapy – management and monitoring.
(a) Drug, Disease State Information – In-depth disclosure of the drug or therapeutic class of drugs or disease state including pharmacology, side effects and interaction.
(b) New Therapeutic Modalities: Expansion of current drug therapy or treatment.
(c) Patient Assessment: Assessment techniques by consultant pharmacist to determine the need and effectiveness of indicated drug therapy along with identification and assessment of side effects on patient’s well-being.
(d) Pertinent Laboratory Tests.
(e) Therapeutic Dosing.
(2) Administrative Responsibilities.
(a) Update on Administrative Responsibilities.
1. Legal requirements including statutes, rules and regulation (Federal and State).
2. The Joint Commission on the Accreditation of Healthcare Organizations.
3. Personnel requirements.
4. Health Insurance Portability and Accountability.
(b) Focus on Consultant Pharmacist Practice Issues/Concerns.
1. How to get things accomplished in complex organizations.
2. Key contacts to be effective as a consultant pharmacist.
3. Considerations and preparation for site inspections.
(3) Consultant Pharmacist Facility Responsibilities. This segment details the requirements in one of the facility types for which a consultant pharmacist is required. Only one practice setting may be included in each program.
(a) Pharmacist-Medication Responsibilities – Assessment mechanism for delivery system, review procedures and monitoring processes.
(b) Pharmacist-Patient Responsibilities – Patient assessment, laboratory test monitoring and therapeutic dosing.
(c) Committee Responsibilities – Make-up and responsibilities for various facility committees.
(d) Reporting requirements.
(4) Compounding sterile or nonsterile human drugs, or both.
Rulemaking Authority 465.005, 465.012, 465.0125 FS. Law Implemented 465.012, 465.0125 FS. History-New 10-14-91, Formerly 21S-26.302, 61F10-26.302, 59X-26.302, Amended 5-5-05, 7-21-09, 2-2-20.
(1) Drug Therapy – Disease State. Patient Drug Therapy – management and monitoring.
(a) Drug, Disease State Information – In-depth disclosure of the drug or therapeutic class of drugs or disease state including pharmacology, side effects and interaction.
(b) New Therapeutic Modalities: Expansion of current drug therapy or treatment.
(c) Patient Assessment: Assessment techniques by consultant pharmacist to determine the need and effectiveness of indicated drug therapy along with identification and assessment of side effects on patient’s well-being.
(d) Pertinent Laboratory Tests.
(e) Therapeutic Dosing.
(2) Administrative Responsibilities.
(a) Update on Administrative Responsibilities.
1. Legal requirements including statutes, rules and regulation (Federal and State).
2. The Joint Commission on the Accreditation of Healthcare Organizations.
3. Personnel requirements.
4. Health Insurance Portability and Accountability.
(b) Focus on Consultant Pharmacist Practice Issues/Concerns.
1. How to get things accomplished in complex organizations.
2. Key contacts to be effective as a consultant pharmacist.
3. Considerations and preparation for site inspections.
(3) Consultant Pharmacist Facility Responsibilities. This segment details the requirements in one of the facility types for which a consultant pharmacist is required. Only one practice setting may be included in each program.
(a) Pharmacist-Medication Responsibilities – Assessment mechanism for delivery system, review procedures and monitoring processes.
(b) Pharmacist-Patient Responsibilities – Patient assessment, laboratory test monitoring and therapeutic dosing.
(c) Committee Responsibilities – Make-up and responsibilities for various facility committees.
(d) Reporting requirements.
(4) Compounding sterile or nonsterile human drugs, or both.
Rulemaking Authority 465.005, 465.012, 465.0125 FS. Law Implemented 465.012, 465.0125 FS. History-New 10-14-91, Formerly 21S-26.302, 61F10-26.302, 59X-26.302, Amended 5-5-05, 7-21-09, 2-2-20.